Physician
Montellano, Franklin
Montellano, Franklin was paid $1.23M by Medicaid between Jan 2018 and Sep 2024, across 100 billing codes. Its largest line is 0202U, Oncology (prostate), multianalyte, gene expression profiling — 14% of everything it billed.
33Billing provider infoMONTELLANO, FRANKLIN
GENEVA, IL 60134
GENEVA, IL 60134
33aNPI1669554663assigned 10/19/2006
33bProvider typeAnatomic Pathology & Clinical Pathology Physician
28Total paid$1.23M
24GClaims197,306
24DCodes billed100
24AFirst – last monthJan 2018 – Sep 2024
Compared with peers
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Illinois
Rank by total paid#56 of 398
Median peer was paid$66K
This provider vs. median19×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,567 | $93K | |
| 2019 | 33,270 | $201K | |
| 2020 | 38,909 | $239K | |
| 2021 | 39,588 | $255K | |
| 2022 | 38,603 | $283K | |
| 2023 | 26,306 | $159K | |
| 2024incomplete | 63 | $3K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 14% | 771 | 733 | $173K |
| 80053 | Comprehensive metabolic panel | 13% | 30,362 | 20,328 | $155K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 8.3% | 3,313 | 2,716 | $102K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 6.9% | 29,981 | 20,022 | $85K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 5.3% | 2,785 | 2,392 | $66K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 4.6% | 336 | 279 | $57K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 2.8% | 1,484 | 1,057 | $35K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 2.7% | 985 | 930 | $33K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.6% | 3,965 | 3,559 | $32K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | 2.5% | 1,379 | 1,333 | $31K |
| 80048 | Basic metabolic panel (calcium, ionized) | 2.4% | 7,262 | 3,172 | $30K |
| 83735 | 2.1% | 7,807 | 3,333 | $26K |
88 more codes
| 85027 | 2.0% | 8,703 | $25K | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 1.6% | 500 | $19K |
| 83690 | 1.3% | 4,829 | $16K | |
| 87040 | 1.3% | 1,532 | $16K | |
| 84484 | 1.2% | 3,146 | $15K | |
| 84703 | 1.1% | 3,847 | $14K | |
| 81001 | 1.1% | 9,872 | $14K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 1,807 | $13K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 2,334 | $12K |
| 82962 | <1% | 6,679 | $12K | |
| 85610 | <1% | 5,657 | $11K | |
| 82607 | <1% | 1,747 | $10K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 171 | $10K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 138 | $10K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 314 | $10K |
| 86140 | <1% | 3,881 | $9K | |
| 86850 | <1% | 2,940 | $8K | |
| 80061 | Lipid panel | <1% | 2,355 | $8K |
| 86901 | <1% | 3,402 | $8K | |
| 87581 | <1% | 335 | $8K | |
| 87486 | <1% | 334 | $8K | |
| 85379 | <1% | 2,005 | $8K | |
| 82746 | <1% | 1,270 | $7K | |
| 84439 | <1% | 1,584 | $7K | |
| 81025 | <1% | 3,590 | $7K | |
| 82550 | <1% | 2,363 | $7K | |
| 85730 | <1% | 2,230 | $7K | |
| 87186 | <1% | 1,065 | $6K | |
| 87631 | <1% | 120 | $6K | |
| 84466 | <1% | 1,364 | $6K | |
| 86900 | <1% | 3,407 | $6K | |
| 83605 | <1% | 1,196 | $6K | |
| 82553 | <1% | 1,446 | $5K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,699 | $5K |
| 83880 | <1% | 473 | $5K | |
| 82728 | <1% | 1,262 | $5K | |
| 82803 | <1% | 589 | $5K | |
| 83615 | <1% | 1,808 | $5K | |
| 83540 | <1% | 1,424 | $4K | |
| 85007 | <1% | 2,163 | $4K | |
| 87641 | <1% | 161 | $4K | |
| 87070 | <1% | 890 | $3K | |
| 85652 | <1% | 2,066 | $3K | |
| 84702 | <1% | 602 | $3K | |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 101 | $2K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 286 | $2K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 41 | $2K |
| 83970 | <1% | 133 | $2K | |
| 87075 | <1% | 317 | $2K | |
| 84100 | <1% | 931 | $2K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 85 | $2K |
| 82570 | <1% | 839 | $2K | |
| 87205 | <1% | 781 | $1K | |
| 87077 | <1% | 180 | $1K | |
| 87081 | <1% | 288 | $800.40 | |
| 83498 | <1% | 96 | $771.24 | |
| 83516 | <1% | 135 | $721.36 | |
| 87807 | <1% | 141 | $638.81 | |
| 85018 | <1% | 546 | $620.81 | |
| 84550 | <1% | 288 | $597.25 | |
| 83021 | <1% | 87 | $554.19 | |
| 82077 | <1% | 53 | $549.08 | |
| 85014 | <1% | 464 | $524.97 | |
| 87340 | <1% | 60 | $398.25 | |
| 80076 | <1% | 105 | $367.25 | |
| 84030 | <1% | 119 | $294.56 | |
| 82261 | <1% | 34 | $280.50 | |
| 82140 | <1% | 63 | $275.31 | |
| 84481 | <1% | 56 | $274.34 | |
| 80050 | General health panel | <1% | 396 | $255.60 |
| 83789 | <1% | 34 | $245.82 | |
| 84156 | <1% | 165 | $192.18 | |
| 84403 | <1% | 13 | $176.96 | |
| 82248 | <1% | 76 | $156.33 | |
| 82776 | <1% | 34 | $119.68 | |
| 86803 | <1% | 12 | $101.04 | |
| 82150 | <1% | 25 | $79.75 | |
| 86880 | <1% | 29 | $75.60 | |
| 87088 | <1% | 14 | $74.32 | |
| 82565 | <1% | 31 | $72.23 | |
| 86308 | <1% | 24 | $57.60 | |
| 82784 | <1% | 13 | $54.48 | |
| 86592 | <1% | 26 | $54.00 | |
| 84134 | <1% | 13 | $50.99 | |
| 84145 | <1% | 371 | $42.68 | |
| 84132 | <1% | 16 | $33.36 | |
| 85045 | <1% | 14 | $18.34 | |
| 80320 | 0% | 41 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.